Index to this page


Several strains of laboratory mice are homozygous for single-gene mutations that causes them to become grossly obese.

These fall into two classes:

  • ob/ob = mutations in the gene for the protein hormone leptin

    When ob/ob mice are treated with injections of leptin they lose their excess fat and return to normal body weight.

  • db/db = mutations in the gene that encodes the receptor for leptin

Study of these animals has led to an understanding of the action of leptin in humans.

Human leptin is a protein of 167 amino acids. It is manufactured in the adipocytes (fat cells) of white adipose tissue, and the level of circulating leptin is directly proportional to the total amount of fat in the body.

Leptin acts on receptors in the hypothalamus of the brain where it:

  • counteracts the effects of neuropeptide Y (a potent feeding stimulant secreted by cells in the gut and in the hypothalamus);
  • counteracts the effects of anandamide (another potent feeding stimulant that binds to the same receptors as THC, the active ingredient of marijuana)
  • promotes the synthesis of α-MSH, an appetite suppressant;
  • the result: inhibition of food intake.

This inhibition is long-term, in contrast to

  • the rapid inhibition of eating by cholecystokinin (CCK) and
  • the slower suppression of hunger between meals mediated by PPY3-36

The absence of a functional hormone (or its receptor) leads to uncontrolled food intake and resulting obesity.

Leptin also acts on hypothalamic neurons responsible for

In addition to its effect on the hypothalamus, leptin acts directly on

  • the cells of the liver and skeletal muscle where it stimulates the oxidation of fatty acids in the mitochondria. This reduces the storage of fat in those tissues.
  • T cells where it enhances the production of Th1 cells promoting inflammation. Mice without leptin are protected from autoimmune disease (which may account for the reports that restricting food intake helps humans with rheumatoid arthritis).

Mutations in the gene for leptin, or in its receptor, are rarely found in obese people.

The rare cases:

  • Extreme obesity in five members of two families that are homozygous for mutations (frameshift in one family, missense in the other) in their leptin gene; i.e., they are like ob/ob mice.
  • Extreme obesity among three members of a family that are homozygous for mutations in their leptin receptor gene; i.e., they are like db/db mice.
  • Only moderate obesity in people who are heterozygous (one mutant and one normal) for their leptin genes.

Recombinant human leptin is now available, but trials to see if it can reduce obesity in humans as it does in ob/ob mice have been disappointing.

However, the 16 September 1999 issue of The New England Journal of Medicine reported the results of a year-long trial of recombinant human leptin in a 9-year-old girl who is homozygous for a frameshift mutation in her leptin genes. The findings:

  • She began the trial weighing 208 pounds (94.4 kg), of which 123 lbs (55.9 kg) was fat (adipose tissue).
  • She was given daily injections of recombinant leptin for one year.
  • At the end of that time,
  • she had lost 36 lbs (16.4 kg), most of it fat.
  • Her appetite and thus food intake had decreased.
  • Her immune system made antileptin antibodies but these did not seem to interfere with the action of the hormone.

But trials of recombinant leptin in obese humans who do not have mutations in both their leptin genes have not shown any great benefit in weight reduction.


Lipodystrophy is the term given for a condition (very rare) in which the person cannot manufacture adipose tissue. With no fat cells, these people do not make leptin, but of course cannot become obese as a result. They do, however, suffer some problems — most often Non Insulin-Dependent Diabetes Mellitus (NIDDM) ("Type 2" diabetes). Treatment with recombinant leptin helps them.


Fat cells in mice also secrete a small protein (108 amino acids) called resistin.

Resistin causes tissues — especially the liver — to be less sensitive to the action of insulin, which is the hallmark of Type 2 diabetes. Blood glucose levels rise because of increased glycogenolysis and gluconeogenesis in the liver.

In humans, resistin is primarily a product of macrophages, not fat cells. Nevertheless, there is a strong association in humans between elevated levels of resistin, obesity, and Type 2 diabetes (over 80% of the people with Type 2 diabetes are obese).

Retinol Binding Protein 4 (RBP4)

This protein (of ~180 amino acids) is responsible for the transport of retinol (vitamin A) in the blood.

When it is secreted in elevated amounts by fat cells, it

  • suppresses glucose uptake by skeletal muscle;
  • enhances glucose release by the liver.

These actions counteract those of insulin. Elevated levels of RBP4 occur in humans with Type 2 diabetes mellitus (NIDDM).

Welcome&Next Search

10 November 2015